(NASDAQ: KMDA) Kamada's forecast annual revenue growth rate of 7.8% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.42%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.37%.
Kamada's revenue in 2025 is $169,517,000.On average, 3 Wall Street analysts forecast KMDA's revenue for 2025 to be $10,399,554,836, with the lowest KMDA revenue forecast at $10,304,901,555, and the highest KMDA revenue forecast at $10,462,465,340. On average, 3 Wall Street analysts forecast KMDA's revenue for 2026 to be $11,439,648,332, with the lowest KMDA revenue forecast at $11,296,863,340, and the highest KMDA revenue forecast at $11,618,891,514.
In 2027, KMDA is forecast to generate $12,130,686,289 in revenue, with the lowest revenue forecast at $11,884,564,757 and the highest revenue forecast at $12,376,807,822.